SMMT vs. BHVN, RARE, IDYA, XENE, PBH, AXSM, CORT, HCM, ARWR, and INSM
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), HUTCHMED (HCM), Arrowhead Pharmaceuticals (ARWR), and Insmed (INSM). These companies are all part of the "pharmaceutical preparations" industry.
Summit Therapeutics (NASDAQ:SMMT) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment.
Summit Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 68.92%. Biohaven has a consensus price target of $51.63, indicating a potential upside of 38.15%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Biohaven.
Summit Therapeutics has a beta of -1.13, meaning that its share price is 213% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Summit Therapeutics' return on equity of -125.07% beat Biohaven's return on equity.
Biohaven received 86 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 65.43% of users gave Biohaven an outperform vote while only 57.00% of users gave Summit Therapeutics an outperform vote.
Biohaven has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biohaven had 26 more articles in the media than Summit Therapeutics. MarketBeat recorded 26 mentions for Biohaven and 0 mentions for Summit Therapeutics. Biohaven's average media sentiment score of 0.45 beat Summit Therapeutics' score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 83.7% of Summit Therapeutics shares are held by insiders. Comparatively, 16.0% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Biohaven beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
